Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers.
Ganymed's discovery engine is one of the most powerful integrated solutions to building an antibody cancer pipeline in the industry. This is because Ganymed has brought together the strongest and most dynamic scientific team for translational medicine.
With a world leading expertise in pinpointing highly specific proprietary targets, Ganymed is building a growing sustainable pipeline of antibody therapeutics targeting solid cancers with high medical need and large market potential.
Ganymed’s lead antibody Claudiximab (iMAB362), is currently in Phase Ib clinical studies against metastatic gastro-esophageal carcinoma.
Ganymed has six further antibody projects in development in solid cancers with high unmet medical need, including melanomas, prostate cancers, lung cancers, breast cancers, colorectal cancers, and head & neck cancers.
Founded in 2001 as a spin-off from the Universities of Mainz and Zurich, the Company is located in Mainz, Germany and has 65 employees.
An der Goldgrube 12